From the highly prevalent diseases such as the age-related macular degenerations (dry and wet) to the rarer, but more numerous diseases s...

While research astounds us on a daily basis with unexpected discoveries, sometimes it is what we don’t know and haven’t bothered to ask is...

Last week saw the first peer-reviewed publication of the LODER RNAi delivery system developed by Israeli biotech Silenseed ( Khvalevsky ...

The skin has always been a target organ of considerable interest to the RNAi Therapeutics industry due to its apparent accessibility for d...

The last few days saw two more eye-catching examples of investors daring to dream big by committing significant early-stage capital to b...

This Monday, Silence Therapeutics held an investor evening in London.  To my surprise, interest in the company and technology was such t...

[ Warning: this blog entry is not about to discuss a very recent development, but rather is intended to compare the liver gene knockdown t...